The gene that affected patient outcome most severely was CDKN2A (P < 1 × 10−10, HR = 2.3, CI = 2.0–2.6), which corresponds to its association with high-grade disease and poor prognosis in some cancer subtypes, such as glioma31 and soft-tissue sarcoma32. This evidence concerns the gene CDKN2A and cancer.